Abstract
Recent decisions regarding hormone-replacement therapy/estrogen-replacement therapy as well as its association with breast cancer have caused confusion for practitioners. This article attempts to elucidate recent controversies and provides a critical review of recent publications. While low-dose hormone-replacement therapy seems to be a reasonable option for symptomatic postmenopausal women, they should be counseled properly regarding their risk of developing or suffering a recurrence of breast cancer.